Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

Nature

Volumn 428, Issue 6979, 2004, Pages 182-185

  Earl, Patricia L ^a   Americo, Jeffrey L ^a   Wyatt, Linda S ^a   Eller, Leigh Anne ^b   Whitbeck, J Charles ^c   Cohen, Gary H ^c   Eisenberg, Roselyn J ^c   Hartmann, Christopher J ^d   Jackson, David L ^d   Kulesh, David A ^d   Martinez, Mark J ^d   Miller, David M ^d   Mucker, Eric M ^d   Schamblin, Joshua D ^d   Zwiers, Susan H ^d   Huggins, John W ^d   Jahrting, Peter B ^d   Moss, Bernard ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; DISEASES; HEALTH CARE; SKIN; VACCINES;

IMMUNOGENICITY; SMALLPOX;

IMMUNOLOGY;

HIGHLY ATTENUATED MODIFIED VACCINIA VIRUS ANKARA SMALLPOX VACCINE; NEUTRALIZING ANTIBODY; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

MEDICINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BIOLOGICAL WARFARE; CONTROLLED STUDY; DRUG SAFETY; HEALTH CARE PERSONNEL; HUMAN; IMMUNIZATION; IMMUNOGENICITY; LICENSING; MONKEY; MONKEYPOX; MONKEYPOX VIRUS; NONHUMAN; PRIORITY JOURNAL; PUSTULE; SIDE EFFECT; SMALLPOX; T LYMPHOCYTE ACTIVATION; VIRUS ATTENUATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CHICK EMBRYO; DNA, VIRAL; FIBROBLASTS; HUMANS; INTERFERON TYPE II; MACACA FASCICULARIS; MODELS, ANIMAL; MONKEYPOX; MONKEYPOX VIRUS; SMALLPOX VACCINE; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL LOAD;

ANIMALIA; MONKEYPOX VIRUS; PRIMATES; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 12144290086     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02331     Document Type: Article

References (30)

1. Fulginiti, V. A., Papier, A., Lane, J. M., Neff, J. M. & Henderson, D. A. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37, 251-271 (2003).
2. Mayr, A., Hochstein-Mintzel, V. & Stickl, H. Abstammung, eigenschaften und verwendung des attenuierten vaccinia-stammes MVA [Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA]. Infection 3, 6-14 (1975).
3. Meyer, H., Sutter, G. & Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72, 1031-1038 (1991).
4. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396 (1998).
5. Carroll, M. & Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238, 198-211 (1997).
6. Drexler, I., Heller, K., Wahren, B., Erfle, V. & Sutter, G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79, 347-352 (1998).
7. Blanchard, T. J., Alcami, A., Andrea, P. & Smith, G. L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79, 1159-1167 (1998).
8. Sutter, G. & Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89, 10847-10851 (1992).
9. Stittelaar, K. J. et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19, 3700-3709 (2001).
10. Hochstein-Mintzel, V., Huber, H.-C. & Stickl, H. Die orale und nasale immuniserung mit poxvirus vacciniae III. Mitteilung: tierexperimentelle untersuchungen [Oral and nasal immunization with poxvirus vaccine. Part III: experimental animal investigations]. Zentralbl. Bakteriol. Hyg. 156, 30-96 (1972).
11. Hochstein-Mintzel, V., Hänichen, T., Huber, H. C. & Stickl, H. Vaccinia- und variolaprotektive wirkung des modifezierten vaccinia-stammes MVA bei intramuskulärer immunisierung [An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola]. Zentralbl. Bakteriol. Hyg. 230, 283-297 (1975).
12. Belyakov, I. M. et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl Acad. Sci. USA 100, 9458-9463 (2003).
13. Stickl, H. et al. MYA-stufenimpfung gegen pocken, klinische erprobung des attenuierten pockenlebendimpfstoffes, stamm MVA [MVA vaccination against smallpox: clinical trials of an attenuated live vaccinia virus strain (MVA)]. Dtsch. Med. Wochenschr. 99, 2386-2392 (1974).
14. Mayr, A., Stickl, H., Müller, H. K., Danner, K. & Singer, H. Der pockenimpfstamm MVA: marker, genetische struktur, erfahrungen mit der parenteralen schutzimpfung und verhalten im abwehrgeschwächten organismus [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with parenteral vaccination and behavior in organisms with debilitated defense mechanism]. Zentralbl. Bakteriol. Hyg. 167, 375-390 (1978).
15. Mayr, A. History of variola, smallpox-eradication and MVA. Berl. Munch. Tierarztl. Wochenschr. 112, 322-328 (1999).
16. Zaucha, G. M., Jahrling, P. B., Geisbert, T. W., Swearengen, J. R. & Hensley, L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81, 1581-1600 (2001).
17. LeDuc, J. W., Damon, I., Relman, D. A., Huggins, J. & Jahrling, P. B. Smallpox research activities: U.S. interagency collaboration, 2001. Emerg. Infect. Dis. 8, 743-745 (2002).
18. Arita, I., Jezek, Z., Khodakevich, L. & Ruti, K. Human monkeypox: a newly emerged orthopoxvirus zoonosis in the tropical rain forests of Africa. Am. J. Trop. Med. Hyg. 34, 781-789 (1985).
19. Breman, J. G. & Henderson, D. A. Poxvirus dilemmas-monkeypox, smallpox, and biologic terrorism. N Engl. J. Med. 339, 556-559 (1998).
20. Smith, G. L., Vanderplasschen, A. & Law, M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83, 2915-2931 (2002).
21. Law, M. & Smith, G. L. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280, 132-142 (2001).
22. Hooper, J. W., Custer, D. M., Schmaljohn, C. S. & Schmaljohn, A. L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266, 329-339 (2000).
23. Hooper, J. W., Custer, D. M. & Thompson, E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306, 181-195 (2003).
24. Galmiche, M. C., Goenaga, J., Wittek, R. & Rindisbacher, L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254, 71-80 (1999).
25. Wolffe, E. J., Vijaya, S. & Moss, B. A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211, 53-63 (1995).
26. Earl, P. L., Americo, J. L. & Moss, B. Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J. Virol. 77, 10684-10688 (2003).
27. Appleyard, G., Hapel, A. J. & Boulter, E. A. An antigenic difference between intracellular and extracellular rabbitpox virus. J. Gen. Virol. 13, 9-17 (1971).
28. Law, M., Hollinshead, R. & Smith, G. L. Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J. Gen. Virol. 83, 209-222 (2002).
29. Breman, J. G. & Henderson, D. A. Diagnosis and management of smallpox. N. Engl. J. Med. 346, 1300-1308 (2002).
30. + T lymphocytes using antigen delivery by a recombinant vaccinia expression vector and intracellular cytokine staining. J. Immunol. Methods 262, 167-180 (2002).